Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Got $200? 2 Dividend Stocks to Buy and Hold Forever
These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.
Johnson & Johnson's SWOT analysis: stock outlook amid pipeline progress, biosimilar challenges
Johnson & Johnson (NYSE:JNJ), a global healthcare leader, finds itself at a pivotal juncture as it navigates a landscape of ...
Hosted on MSN1d
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $147.77, marking a +1.93% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.21%. Elsewhere ...
Johnson & Johnson’s Strategic Acquisition of Intra-Cellular Therapies: Balancing Short-term Dilution with Long-term Growth Potential
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim ...
FiercePharma5d
JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B
At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that ...
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...